Introducing Violet(TM) Iodine, New Once-Daily,
Introducing Violet(TM) Iodine, New Once-Daily, Non-Prescription Pill For Relief Of Premenstrual Breast Discomfort*
Formulated to Help Alleviate Symptoms Associated with Fibrocystic Breast Condition for the Estimated 50 Percent of Women Aged 15 to 49 Who Suffer from Monthly Breast Discomfort
MENLO PARK, Calif., Dec. 9, 2014 /PRNewswire/ -- BioPharmX Corporation (OTCQB: BPMX) today announced the availability of Violet(TM) iodine, a new, once-daily pill for relief of premenstrual breast discomfort. The first-of-its-kind product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a condition known as fibrocystic breast condition (FBC), with the added benefit of promoting breast health for women of reproductive age.*
To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/737895...discomfort
"Fibrocystic breast condition is the generally accepted term to describe a common, benign condition that is associated with varying levels of monthly breast discomfort, including breast tenderness, aches, swelling, and heaviness," said Dr. Lisa Masterson, OBGYN. "FBC affects an estimated 50 percent of women between the ages of 15-49,(1) or over 35 million women in America, which is why I am thrilled there is now an option for my patients and the many women living with this condition to manage their discomfort."
Fibrocystic breast condition is thought to be caused by hormonal imbalances, which can cause breast tissue growth to exceed its natural cell turnover. Breast tissue builds up month after month with each menstrual cycle, resulting in swollen, achy and tender breasts.
Daily use of Violet iodine can help normalize these imbalances and address the underlying causes of fibrocystic breast condition, thereby alleviating symptoms that vary in severity from general soreness to clinically diagnosed FBC.* One clinical study showed that women taking a daily dose of either 3 or 6 mg of iodine showed a decrease in monthly breast discomfort relative to women taking a daily dose of either a placebo or 1.5 mg of iodine.(1*)
"What is unique about Violet iodine is its non-hormonal formula of patented molecular iodine, which aims to target the breast tissue with limited introduction in the thyroid,"* said Dr. Lee P. Shulman, Professor and Head of the Section of Reproductive Genetics in the Department of Obstetrics and Gynecology at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois. "Adding Violet iodine to a woman's daily regimen can help safely relieve the most common forms of breast pain and discomfort, including aches and swelling, while also maintaining healthy breast tissue."*
When taken daily, Violet iodine can begin to provide relief of symptoms after several months or approximately two menstrual cycles, though some women see relief much sooner.* Beyond FBC, Violet iodine can support women through breast tissue changes over the course of their lives by maintaining healthy cell growth -- from onset of menstruation to menopause.* Daily consumption of iodine is typically safe for most people.
"Discomfort from monthly breast pain associated with fibrocystic breast condition can impact a woman's lifestyle, from restricting the types of clothes she wears and limiting her ability to exercise regularly to preventing her from hugging loved ones," said Anja Krammer, President, BioPharmX. "We're excited to finally bring to market a product in Violet iodine that will help the millions of women whose breast discomfort has interfered with their daily lives for far too long."*
Violet iodine is now available for sale online without a prescription in 30 and 60 count packages and can be found in the feminine care aisle of major retailers beginning 2015.
About Violet(TM) Iodine
Violet iodine is a daily iodine supplement for the relief of the most common symptoms of cyclic mastalgia and fibrocystic breast condition (FBC), including monthly swelling, tenderness, aches and heaviness. Violet iodine is available in 30 and 60 count packages at Walgreen Co.'s (NYSE: WAG) (NASDAQ: WAG) drugstore.com(TM) web store. To learn more about Violet iodine, visit www.VioletDaily.com.
BioPharmX Corporation (BPMX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Making Jobs Accessible for Kidney Patients Well, things are stirring up on Capitol Hill, and it's high time, if you ask me. The American Association of Kidney Patients (AAKP) is rallying hard for a bipartisan bill that could change the landscape for folks grappling with kidney diseases and disabilities. You’ve got Reps Pete Sessions and Steny Hoyer pushing this American...
Continue Reading
Diving Into Hyperliquid's $100 Million Bold Move Let’s cut through the corporate fluff—Hyperliquid Strategies Inc. just cranked up their stock repurchase program to a cool $100 million. Yep, that’s right—the brain trust behind NASDAQ:PURR has pulled out the checkbook to buy more of its own shares. This decision, unveiled on October 23, 2026, is like tossing a...
Continue Reading
Moo-ving Towards a New Record Alright, listen up. This fall, there's a bovine spectacle coming to Maryland that's more than just a trip down to the fairgrounds—it's Cowfest 2026, baby! Now, if you're scratching your head thinking this is just another seasonal shindig, you're underestimating what's mooing across Frederick County. The Flying Cows are ready to take the...
Continue Reading
A Juicy Rivalry with Sweet and Savory Stakes You ever catch yourself watching state pride turn into a marketing showdown? That's what's cookin' with Wisconsin's Johnsonville and Florida's Natural, and believe me, this isn't just about what’s on your plate. Forget the foam fingers, here it's all about the brats and the OJ. It's like the Packers versus the Dolphins, but...
Continue Reading
Breaking into Westview Promenade The Big Greek Café is making a bold play in Frederick County, Maryland, choosing Westview Promenade for its second local spot. You know they're not just picking any old place; they're setting up shop at a bustling 200,000 square foot lifestyle center. This expansion marks a significant move as they join hands with Hill Management Services...
Continue Reading
Celebrating a Legend in the Heart of San Francisco The Bay Area is set to become home to a vibrant new center dedicated to celebrating the multifaceted legacy of Jerry Garcia, Grateful Dead co-founder. Announced by the Garcia family, with the help of archival platform Starchive and project coordinator Christopher McCutcheon, the Jerry Garcia Music Arts Center promises to...
Continue Reading
Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...
Continue Reading
The Rise and Fall of Netcapital: A Troubling Drop Netcapital Inc. (NASDAQ: NCPL) has found itself in hot water with investors after revelations of a wild scheme to fluff up its revenue figures. It’s like watching a house of cards crumble — and investors are left holding the bag. From December 15, 2021, through September 3, 2026, a slew of misinformation allegedly...
Continue Reading
Storm Clouds Over Anavex: What Investors Need to Know If you've got a slice of Anavex Life Sciences Corp. (NASDAQ: AVXL) in your portfolio, the latest chapter of their legal saga feels less like a twist and more like a twist of the knife. These lawsuits often come out of left field for investors, but this one seems like a slow train that’s been gathering steam for a...
Continue Reading
Expanding the Boardroom with Healthcare Expertise In an unexpected twist for Civista Bancshares (NASDAQ: CIVB), the financial holding company is roping in some healthcare brass to its board. Jeremy Normington-Slay just snagged a seat at Civista's table, and he's bringing his tough-sledding healthcare leadership chops straight from Firelands Health. A $4.3 billion outfit...
Continue Reading
Top 5 Most Recently Viewed Articles
Investment Returns of Republic Services Explained Investing over a long period can significantly impact the value of your investment. One compelling example is Republic Services (RSG), which has demonstrated remarkable growth over the past 15 years. With an impressive annual return of 20.96%, Republic Services has outperformed many market benchmarks by a notable 8.71%...
Continue Reading
Innovative Haptic Technology from bHaptics bHaptics has made a significant leap in the world of immersive experiences with the introduction of their latest products, the TactSuit Pro and TactSuit Air. This marks the company's first product launch in four years, showcasing their commitment to innovation in haptic technology. With a focus on delivering premium experiences...
Continue Reading
Understanding Current Investor Sentiment on S&P Global Recently, there has been a noticeable increase in short interest for S&P Global (SPGI). The percentage of short shares has climbed to 3.23%, reflecting a total of 2.94 million shares sold short. This figure comprises 0.96% of the total shares available for trading. Analysts believe that based on the current trading...
Continue Reading
Shell plc Shares Buyback Announcement Transaction in Own Shares Shell plc recently announced the execution of share purchases as a vital component of its ongoing share buyback program. Details of Share Purchases The total number of shares purchased for cancellation on the mentioned date amounted to 266,073, 180,953, and 150,405 across various venues, showcasing the...
Continue Reading
Mexico Equity and Income Fund Dividend Declaration In a recent announcement that is sure to excite investors, the Mexico Equity and Income Fund, Inc. (NYSE: MXE) has declared a cash dividend of $0.2337 per share on its common stock. This dividend is a year-end offering that consists entirely of ordinary income, demonstrating the Fund's commitment to returning value to its...
Continue Reading